Ascendis Pharma Stock Price, News & Analysis

The report titled "Non-Viral / Intracellular Drug Delivery Systems Market" by ResearchAndMarkets.com highlights the rising demand for efficient drug delivery systems in the biopharmaceutical industry. It notes that over 20% of the proteome resides within cell membranes, necessitating innovative delivery methods for therapeutic intervention. Key advancements include non-viral systems such as exosome-based techniques and cell-penetrating peptides. The report reveals that around 1,300 patents have been filed, indicating substantial innovation, with over 20,000 studies on oligonucleotide-based therapeutics underway. The market is expected to grow significantly in the near term.

Ascendis Pharma (ASND) reported a positive update on its Vision 3x3 strategic plan, spotlighting upcoming milestones for 2023. Key developments include the anticipated launch of TransCon PTH for hypoparathyroidism, with FDA Priority Review due on April 30, 2023. The company also expects topline results from the Phase 3 foresiGHt Trial in Q4 2023 and plans to launch SKYTROFA in Germany by Q3 2023. TransCon CNP's Phase 2 trials show potential for children with achondroplasia, marking advances across its endocrinology, oncology, and ophthalmology pipelines.

Ascendis Pharma announces the opening of the online portal for the Expanded Access Program (EAP) allowing physicians to request access to TransCon PTH for eligible patients in the U.S. This investigational parathyroid hormone replacement therapy is currently under Priority Review by the FDA, with a PDUFA date set for April 30, 2023. Patients eligible for the program must be adults diagnosed with hypoparathyroidism and meet specific inclusion and exclusion criteria. The move aims to address the needs of the hypopara community while awaiting potential FDA approval.

Ascendis Pharma A/S (Nasdaq: ASND) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023. The event takes place in San Francisco, CA, from 12:00 to 12:40 p.m. Eastern Time. A live webcast will be available on the Ascendis Pharma website, with a replay accessible for 30 days post-event. The company focuses on integrating a global biopharma approach using its TransCon platform aimed at developing innovative therapies to improve patient lives.

Ascendis Pharma (ASND) announced an expanded access program for its investigational therapy, TransCon PTH, aimed at patients with hypoparathyroidism in the U.S. The program allows eligible patients, who cannot access other treatments, to request this therapy through their physicians. TransCon PTH is currently under FDA Priority Review, with a target PDUFA date of April 30, 2023. The company emphasizes its commitment to addressing the urgent needs of the hypopara community while underscoring that TransCon PTH's safety and efficacy are not yet established.

Ascendis Pharma (Nasdaq: ASND) will participate in the 5th Annual Evercore ISI HealthCONx Conference on December 1, 2022. The event, hosted virtually, features a fireside chat with the company's executives, scheduled from 1:00 PM to 1:20 PM Eastern Time.

A live webcast will be accessible via the Ascendis Pharma website, with a replay available for 30 days post-event. Ascendis Pharma focuses on innovative therapies using its TransCon technology to enhance patient care, with operations in multiple global locations.

Ascendis Pharma has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency for TransCon PTH, a potential first treatment for hypoparathyroidism. This condition affects an estimated 85,000-223,000 patients in Europe and currently lacks effective hormonal replacement therapy. The MAA is based on data from the Phase 3 PaTHway Trial, where 77 out of 79 patients continued treatment, indicating strong efficacy and tolerability. The FDA is currently reviewing TransCon PTH, with a target action date of April 30, 2023.

Ascendis Pharma announced positive topline results from the ACcomplisH Trial, a Phase 2 study evaluating the efficacy of once-weekly TransCon CNP in children with achondroplasia. The trial demonstrated a statistically significant improvement in annualized height velocity (AHV) at 52 weeks for the 100 µg/kg/week dose compared to placebo (p=0.0218). Remarkably, all 57 participants completed the trial, indicating robust tolerability. These findings support further development of TransCon CNP as a treatment option for achondroplasia. Ascendis will discuss these results in a conference call on November 14, 2022.

Ascendis Pharma (Nasdaq: ASND) has provided new data from the Phase 1/2 transcendIT-101 trial of TransCon TLR7/8 Agonist for advanced solid tumors. Results show early signs of clinical activity when used alone or with pembrolizumab, along with no systemic toxicity. The treatment demonstrated sustained immune system engagement after one injection. The recommended Phase 2 dose was established at 0.5 mg/lesion. Ongoing trials will further investigate its efficacy against various cancer types. Results were presented at the Society for Immunotherapy of Cancer annual meeting.